By Manling Peng, Weiqi Lu, Lucia Beviglia, Stefan Niewiarowski, and Edward P. Kirby Echicetin, a new protein isolated from Echis carinatus venom by reverse phase and ion exchange chromatography specifically inhibited agglutination of fixed platelets induced by several platelet glycoprotein Ib (GPlb) agonists, such as bovine von Willebrand factor (vWF), alboaggregins, and human vWF in the presence of botrocetin. Unlike alboaggregins, echicetin bound to GPlb but did not induce agglutination of washed or fixed platelets. In contrast to disintegrins, it did not block adenosine 5-diphosphate (ADP)-induced platelet aggregation in the presence of fibrinogen. The apparent molecular weight of echicetin measured on sodium dodecyl sulfate (SDS) gel electrophoresis was 26
Kd under nonreducing conditions. On reduction, echicetin showed 1 6 and 14-Kd subunits suggesting that the molecule is a dimer. Reduced echicetin retained its binding ac-
HE INTERACTION between platelet glycoprotein Ib
T (GPIb) and von Willebrand factor (vWF) plays a key role in the initial contact adhesion of platelets to the exposed subendothelium. Human vWF circulates in plasma as a series of disulfide-linked multimers ranging in molecular weight from 350,000 to 1 X IO6.' Binding of human vWF to platelets in vitro occurs in the presence of ristocetin, a glycopeptide antibiotic' or botrocetin, a snake venom p r~t e i n ,~.~ whereas bovine vWF directly induces platelet aggl~tination.~ Bovine and human vWF bind to the same region on platelet GPIb. 6 GPIb is present on the platelet plasma membrane as a disulfide-linked heterodimer composed of an a-chain (GPIba) and a &chain (GPIbj3).7 Both chains appear to be integral membrane glycoproteins containing hydrophobic transmembrane domains. 8 The extracellular N-terminal region of GPIba can be cleaved by an endogenous calcium-dependent sulfhydryl protease, giving rise to glyco~alicin.~ Further digestion of glycocalicin with trypsin yields a highly glycosylated polypeptide fragment termed "macroglycopeptide" of 118 Kd and a smaller fragment of 45 Kd." The 45 Kd fragment includes the amino terminus of GPIba and contains binding sites for vWF."*'* Botrocetin, a partially purified protein from the venom of the South American pit viper, Bothrops jararaca, has previously been shown to cause the human vWF-dependent agglutination of platelet^.^^^ Studies with immobilized botrocetin showed that botrocetin binds to a 52148-Kd region of vWF that contains the GPIb binding domain. It does not bind to glycocalicin. I Ristocetin is another cofactor for human vWF binding to platelet GPIb. Unlike botrocetin, it is not clear whether ristocetin promotes the binding of vWF to platelet GPIb by interacting with the vWF molecule or with its receptor on GPIb.14 Alboaggregins, a family of snake venom proteins isolated from Trimeresurus albolabris venom, agglutinate platelets directly without the need for any cofactor. They compete with vWF for binding to platelet GPIb.L5*'6 We report here the purification of a related protein from Echis carinatus venom that specifically inhibits the binding of alboaggregin and vWF to platelet GPIb without inducing platelet agglutination and determination of echicetin's biological functions in vivo.
tivity and its inhibitory effect on the agglutination of fixed platelets induced by bovine vWF. '251-echicetin bound to fixed platelets with high affinity (kd = 30 -C 1.8 nmol/L) at 45,000 k 2,400 binding sites per platelet. The binding was selectively inhibited by a monoclonal antibody to the 45-Kd N-terminal domain of platelet GPlb, but not by monoclonal antibodies to other regions on GPlb. Binding of '251-bovine vWF to fixed platelets was strongly inhibited by echicetin. In contrast, bovine vWF showed a much weaker inhibitory activity on binding of '251-echicetin to platelets. The half life of echicetin in blood was approximately 170 minutes with no detectable degradation. Echicetin significantly prolonged the bleeding time of mice, suggesting that it may inhibit vWF binding to GPlb in vivo as well as in vitro.
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MATERIALS AND METHODS
Lyophilized E carinatus venom (lot No. 1 18F0684), adenosine 5'-diphosphate (ADP), dithiothreitol (DTT), iodoacetamide (IAA) and chloramine T were purchased from Sigma Chemical Co (St Louis, MO). Fibrinogen (grade L) was from Kabi Vitrum (Stockholm, Sweden). IodoGen was from Pierce Chemical Co (Rockford, IL). Monoclonal antibodies AKI, AK2, AK3 and FMC 25 were supplied by Dr Michael Berndt (Research Center for Thrombosis and Cardiovascular Disease, Department of Medicine, University of Sydney, Westmead, NSW, Australia). Echistatin was prepared by reverse phase high-performance liquid chromatography (HPLC)" from the same lot ofE carinatus venom from which echicetin was isolated. Botrocetin was a gift from Dr John Holt (Rhhe-Poulenc Rorer Biotechnology Inc, King of Prussia, PA). Serratia marcescens protease was purified according to the method described by Cooper et a1.I' Alboaggregin-A (AL-A), alboaggregin-B (AL-B) and alboaggregin-C (AL-C) were purified as described by Peng et Human vWF was prepared as described by Bakhshi and Kirby.I9 Bovine vWF was purified as described by Mascelli et al. ' " Lyophilized E carinatus venom was dissolved at 20 mg/mL in 0. I% (vol/vol) trifluoroacetic acid (TFA) (Fisher Scientific, Fair Lawn, NJ). Undissolved components were removed by centrifugation. The supernatant was filtered before reverse-phase chromatography (Vydac TPRP CIS; The Separation Group, Hesperia, CA). The column was extensively washed with starting buffer (0.1% TFA) before applying a linear gradient of 0 to 80% acetonitrille in 0.1% TFA. A11 fractions were lyophilized in a SpeedVac and redissolved in 100 pL of 0.05 mol/L Tris-saline buffer, pH 7.4. They were assayed for their inhibitory effects on bovine vWFPurification qf echicetin. IodoGen. The reaction mixture was incubated for IO minutes at mom temperature with gentle agitation. The reaction was stopped by adding 100 pL of a saturated solution of tyrosine.
2322

PENG ET AL
Labeled proteins were separated from free NaI2'1 and iodotyrosine on Sephadex G-25 columns (Sigma Chemical Co, St Louis, MO). The specific activity of labeled proteins was between 0.3 and I .O X io9 cpm/mg.
Binding of 'z51-proteins to fixed platelets, The binding of lz'L bovine vWF and '2slechicetin to platelets was measured as previously described.'J Labeled proteins were preincubated with either 0.05 mol/ L Tris-saline buffer or unlabeled proteins before the addition of 300 pL platelet suspensions (3 X IO* platelets/mL). The mixtures were allowed to incubate at 37°C for 5 minutes. Bound proteins was sep arated from free proteins by centrifugation in an Eppendorfcentrifuge for 2 minutes at 12, OOOg. The supematants were carefully removed with a glass capillary pipette. Nonspecific binding was determined in the presence of excess unlabeled proteins.
Interaction of echicetin with platelets preincubated with S marcescens prutease. Aliquots of fixed platelet suspensions (1.8 X IO9 platelets/mL) were preincubated with ( I ) 0.05 mol/L Tris-O.1 mol/ L NaCl buffer pH 7.4. (2) S murcescens protease (9.0 pg/mL). or (3) echicetin (10.9 pg/mL). The amount of echicetin used strongly inhibited bovine vWF-induced platelet agglutination. All mixtures were allowed to incubate at 37°C. Bovine vWF-induced agglutination of the three aliquots of platelets was measured every 5 minutes, until S murcescens protease-treated platelets no longer responded to bovine vWF stimulation. The incubation was terminated by adding IO mmol/ L EDTA to all three platelet suspensions. Platelet suspensions were then centrifuged at 12. OOOg for 2 minutes. The supematants were carefully removed from pellets. The pellets were dissolved in 10% For Clearance o f '*'l-echicetin was measured by injecting 0.2 mL o f labeled echicetin (22 X IO3 cpm/mouse) intravenously through the tail vein. Blood samples (0.7 mL) were collected by cardiac puncture from groups o f mice at the different periods. Radioactivity in blood samples was determined in a gamma counter as total radioactivity. Samples were then centrifuged for 30 minutes at 1.500g to obtain the pellets and the supernatants (PPP). Precipitation of '*'I-echicetin in PPP was done by adding 20% trichloroacetic acid (TCA). Samples were incubated at 4OC for IO minutes and then centrifuged again at 1,500g for IO minutes. Radioactivity in the supernatants was counted.
66-
45-
36-
29-24-
20-
14-N R
The half-life of echicetin in blood was calculated according to the formula Ct = Co e-K+ where t is the time, Co is an initial concentration of echicetin. and K+ is the rate constant. was shown in the lower panel.
RESULTS
Characterization ofpirrijied echicetin. Chromatography of crude E carinatirs venom was performed on a CIS reversephase column. The fraction eluting at 5 I % acetonitrile had most of the inhibitory activity toward platelet agglutination induced by bovine vWF (Fig IA) . Further chromatography of this partially purified fraction was camed out on a Mono-S column (Fig IB) . Fraction 9 eluted at about 0.17 mol/L NaCI. It contained a majority of the activity toward bovine vWF-induced platelet agglutination and was best separated from other proteins. It was named echicetin. Five fractions I3 to 16 also showed inhibitory activity suggesting the presence of multiple inhibitors in E carinatirs venom. Echicetin was s e lected as a representative of the whole family of proteins. showed a single protein band corresponding to an apparent molecular weight of about 26 Kd under nonreducing conditions and two bands of 16 Kd and 14 Kd after reduction (Fig 2) , suggesting that echicetin is a heterodimer. '251-echicetin migrated with the same mobility as unlabeled echicetin on SDS-gel electrophoresis. Reduction of 1251-echicetin showed that only the 14-Kd subunit of echicetin was well labeled.
Determination of the apparent molecular weight of echicetin was performed on SDS-gel electrophoresis. Echicetin
Inhibition of agglutination of washed and j x e d platelets. Agglutination of fixed platelets induced by bovine vWF, AL-B, or by human vWF in the presence of botrocetin was inhibited by echicetin in a dose-dependent manner (Fig   3) . An inhibitory effect was also found on agglutination of washed platelets induced by bovine vWF (data not shown). The concentrations of echicetin required for 50% inhibition of bovine vWF-induced agglutination of washed or fixed platelets were approximately 0.15 pg/mL and 0.4 pg/mL, respectively. The concentrations of echicetin needed for the same amount of inhibition of agglutination of fixed platelets induced by botrocetin/human vWF or AL-B were about 1.1 pg/mL and I .05 pg/mL, respectively.
Echicetin had no effect on aggregation of washed platelets by ADP (10 pmol/L) in the presence of fibrinogen (0.24 mg/ mL) (data not shown). (Fig 5) . Scatchard analysis of echicetin binding to platelets from three similar experiments showed one class of binding site with kd = 30 k 1.8 nmol/L (insert). There were approximately 45,000 f 2,400 binding sites per platelet.
The inhibitory effect of reduced echicetin (mixture of unlabeled with labeled echicetin) on platelet agglutination induced by bovine vWF was measured by comparison with unreduced echicetin. The results showed that reduced echicetin had a similar inhibitory activity to unreduced echicetin (Fig 6A) . To determine the binding activity of reduced echicetin to platelets, '251-echicetin was reduced with DTT and alkylated with IAA. The specific binding of reduced 1251-echicetin to platelets was measured by competing the binding with unlabeled native echicetin. Reduction of 1251-echicetin did not alter its binding activity (Fig 6B) . Reduced unlabeled-echicetin effectively competed
Biologic activities of reduced echicetin.
For Bleeding times longer than 10 minutes were recorded as 10 minutes.
the binding of unreduced '251-echicetin to platelets as well (data not shown).
Competition between echicetin, v WF, AL-B, and otherproteins for binding to platelets. The IC50 of unlabeled bovine vWF for inhibition of '251-bovine vWF binding to platelets was approximately 5 pg/mL. Echicetin strongly inhibited binding of 1251-bovine vWF to fixed platelets (Fig 7A) . The ICs0 of echicetin was only 0.2 pg/mL. Inhibition of vWF binding to GPIb by echicetin was not attributable to proteolysis of GPIb by contaminants in the echicetin, as shown by electrophoresis of supernatants of untreated, echicetintreated and S marcescens protease-treated platelets. An approximately 100-Kd peptide appeared only in the supernatant of S marcescens protease-treated platelets. This cleaved peptide is a part of GPIb called glycocalicin that has the binding domain for vWF.~ There was no distinguishable difference between the supernatants and dissolved pellets of untreated and echicetin-treated platelets on SDS-gel electrophoresis.
Binding of 1251-echicetin to platelets was competed by unlabeled echicetin and by AL-B at approximately equal concentrations (ICs0 = 0.5 pg/mL) (Fig 7B) indicating that both molecules had a similar binding affinity for GPIb. However, bovine vWF could only weakly inhibit the binding of 1251-echicetin to platelets (IC50 > 20 pg/mL). On a molar basis, IC50 of bovine vWF for competing binding of 1251-bovine vWF was 9.5 nmol/L (one subunit of bovine vWF was 230 Kd), whereas ICs0 of echicetin was only 2.2 nmol/L. These results showed that, although echicetin, AL-B, and bovine vWF all bound to platelet GPIb, echicetin and AL-B had a greater binding affinity than bovine vWF.
Botrocetin alone at 4.6 pg/mL did not inhibit or promote 1251-echicetin (30 ng/mL) binding to platelets. In contrast, in the presence of human vWF (8.9 pg/mL), 2.3 pg/mL of botrocetin completely inhibited '251-echicetin binding to platelets. This is consistent with the observation by Read et alZ5 that botrocetin first binds to human vWF to form a complex, which then binds to GPIb to cause platelet agglutination. Echistatin (38.9 pg/mL), an RGD containing peptide isolated from E carinatus venom, did not alter 1251-echicetin binding (data not shown).
Determination of binding domain for echicetin on platelet
GPIb. Monoclonal antibody AK2, which is directed against the 45-Kd N-terminal domain of GPIb, strongly inhibited the binding of echicetin and bovine vWF to fixed platelets with IC50s of 0.8 pg/mL and 0.3 pg/mL, respectively. Monoclonal antibodies AK3 and AKl (against epitopes on the macroglycopeptide region of GPIb and the membrane-associated region of the GPIb-IX complex) and FMC 25 (directed against GPIX) had no effect on binding of echicetin to platelets (data not shown).
Binding of '"I-echicetin to erythrocytes and neutrophils. 1251-echicetin did not bind significantly to either human erythrocytes or neutrophils. The percentages of total binding and nonspecific binding were I .23% and 1.1 % for neutrophils, and 3.16% and 2.06% for erythrocytes, respectively.
Interaction of echicetin and alboaggregins with rabbit, rat, pig, and mouse platelets. We found that echicetin, AL-B, and bovine vWF failed to bind to platelets in PRP from rabbits or to induce platelet agglutination, even though platelets in PRP were fully responsive to ADP stimulation. Echicetin as well as other alboaggregins were able to bind to platelets from rat, pig, and mouse. AL-B and AL-C induced aggluti- nation of platelets from rat; however, only AL-B was able to induce agglutination of platelets from pig and mouse.
Efects of echicetin on bleeding time and platelet counts of mice in vivo. The bleeding time of control mice (injected with buffer) was 1.54 k 0.32 minutes (n = 9). Three other groups of mice that were injected with various concentrations of echicetin (0.12, 0.5, and 2.0 pg per mouse) showed significantly prolonged bleeding time one minute after injection (Fig 8) . Echistatin (2.0 pg per mouse) also caused a prolongation of bleeding time similar to echicetin (data not shown). Platelet counts dropped from 112 k 17.5 X 104/pL before injection to 44.5 k 13 X 104/pL 5 minutes after injection of echicetin, 0.25 pg per mouse (40% of initial value). Platelet counts increased thereafter to 52.5 k 14 X 104/pL 30 minutes after injection (47% of initial value) and 75.3 k 11.6 X IO4/ pL 60 minutes after injection (67.2% of initial value), respectively (Fig 9) . Bleeding time 60 minutes after injection of echicetin (0.25 pg per mouse) was longer than 10 minutes (n = 4) (data not shown).
After intravenous injection of '251-echicetin, radioactivity was measured in blood samples (0.7 mL) collected at 3 minutes, 5 minutes, 10 minutes, 30 minutes, and 90 minutes (Fig 10) . The half life of L251-echicetin was determined to be approximately 170 minutes. Radioactivity in the supernatant after TCA precipitation of PPP from all assayed samples was around 8.8% of total radioactivity. This portion of radioactivity probably represented free lZ5I in the sample. This was confirmed by measurement of TCA precipitation of L251-echicetin directly. We also found the radioactivity associated with the cell pellet had a slight tendency to increase (data not shown), so that the decrease of total radioactivity in blood reflected primarily the decrease of radioactivity in the supernatant of plasma.
Measurement of clearance of '2sI-echicetin.
DISCUSSION
Over the past years, a number of investigators have presented strong evidence that monoclonal antibodies directed against the GPIIb/IIIa complex,26 the di~integrins,~~.~' and short RGDX peptidesz9 have potential application in the treatment of platelet thromboembolism. This approach is based on the inhibition of fibrinogen and vWF binding to the GPIIb/IIIa complex. Echicetin, a representative of another snake venom-derived protein family inhibits vWF-induced platelet agglutination by binding to GPIb through a mechanism that is distinguishable from the one of disintegrin family proteins.
Although alboaggregins share many features in common with echicetin, and they all bind to GPIb at the same or closely related sites, the differences between two classes of proteins in terms of biologic function and molecular structure are significant. Alboaggregins function as agonists of platelets, whereas echicetin is an antagonist. Echicetin bound weakly to Mono-Q (a strong anion exchange resin used for purifying alboaggregins16), but bound well to Mono-S (a strong cation exchange resin) suggesting that alboaggregins and echicetin may differ significantly in their content of charged amino acids.
The existence of multiple inhibitors in E carinatus venom may have been attributable to the starting material being a mixture of venoms collected from different snakes, of different ages, at different seasons, or may represent an intrinsic heterogeneity in the venom proteins of this species. Similar variations were also seen in the alboaggregins purified from T afbofabris venoms16 and in the GPIIb/IIIa
Responsiveness to echicetin was found in platelets from rat, pig, and mouse but not in platelets from rabbit. Echicetin significantly prolonged the bleeding times of mice indicating that echicetin may act through a similar mechanism in vivo as in vitro by binding to GPIb so that vWF-induced primary platelet adhesion to subendothelium might be blocked. After 5 minutes of injection of echicetin, a drop of platelet count occurred and platelets gradually rebounded thereafter. Because the half-life of echicetin in blood was approximately 170 minutes, the increase of platelet counts was not a result of the elimination of echicetin from the circulation. The bleeding time retained significantly prolonged up to 60 minutes after injection of echicetin indicating that there was no apparent degradation of this protein in blood over this time period. The actual mechanism of the moderate thrombocytopenia produced by echicetin administration remains to be further investigated. Similar thrombocytopenia is also found following injection into baboons and mice of disintegrins isolated from various snake venom^.^'.^^ In contrast, disintegrins do not cause a decrease of platelet count in hamster and dog, although they do prolong bleeding time. 33.34 Echicetin selectively bound to platelets but not to erythrocytes and neutrophils. Exploration of the antithrombotic potential of echicetin or its active fragments warrants further investigation. 
